Review Article

**In vitro and in silico liver models: Current trends, challenges and opportunities**

Andrey Poloznikov\(^1\), Irina Gazaryan\(^3\), Maxim Shkurnikov\(^4\), Sergey Nikulin\(^1\), Oxana Drapkina\(^7\), Ancha Baranova\(^6\)\(^,\)\(^8\)\(^,\)\(^9\) and Alexander Tonevitsky\(^1\)\(^,\)\(^10\)\(^,\)\(^11\)

\(^1\)Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia; \(^2\)Far Eastern Federal University, Vladivostok, Russia; \(^3\)Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; \(^4\)Department of Cell Biology and Anatomy, School of Medicine, New York Medical College, Valhalla, NY, USA; \(^5\)Department of Chemistry and Physical Sciences, Dyson College, Pace University, Pleasantville, NY, USA; \(^6\)Moscow Institute of Physics and Technology, Dolgoprudny, Moscow, Russia; \(^7\)National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; \(^8\)School of Systems Biology, George Mason University (GMU), Fairfax, VA, USA; \(^9\)Federal State Budgetary Institution “Research Centre for Medical Genetics”, Moscow, Russia; \(^10\)Higher School of Economics, Moscow, Russia; \(^11\)art photonics GmbH, Berlin, Germany

**Summary**

Most common drug development failures originate from either bioavailability problems, or unexpected toxic effects. The culprit is often the liver, which is responsible for biotransformation of a majority of xenobiotics. Liver may be modeled using “liver on a chip” devices, which may include established cell lines, primary human cells, and stem cell-derived hepatocyte-like cells. The choice of biological material along with its processing and maintenance greatly influence both the device performance and the resultant toxicity predictions. Impediments to the development of “liver on a chip” technology include the problems with standardization of cells, limitations imposed by culturing and the necessity to develop more complicated fluidic contours. Fortunately, recent breakthroughs in the development of cell-based reporters, including ones with fluorescent label, permits monitoring of the behavior of the cells embed into the “liver on a chip” devices. Finally, a set of computational approaches has been developed to model both particular toxic response and the homeostasis of human liver as a whole; these approaches pave a way to enhance the in silico stage of assessment for a potential toxicity.

**Keywords:** liver toxicity, DILI, high throughput screening, luciferase fusion reporters, in silico modeling

**1 Introduction**

Drug development becomes more and more expensive: it takes 12-15 years and in a neighborhood of two billion dollars to bring a single drug into the market. Current paradigm of the drug discovery relies on high throughput screening (HTS) of chemical libraries to identify compounds which bind purified target molecules produced by means of genetic engineering (Coussens et al., 2017; Raucy and Lasker, 2010). Lead compounds identified in HTS in vitro assays are subjected to secondary screens in established cell models before proceeding into animal testing. Currently, there is a substantial push for the development of standardized cell-based assays compatible with HTS format (Nickischer et al., 2018; Xia and Wong, 2012) or even the whole-animal assays (Delvecchio et al., 2011; O’Reilly et al., 2014; Pandey and Nichols, 2011).

Using human-derived cell line-based assays as the secondary screen has a number of advantages, the most important one being that cultivated cells are very close in their composition and metabolite concentrations to the cells in the human body. This characteristic helps to deprioritize drug candidates incapable of competing with endogenous co-substrates or co-ligands. Moreover, the compounds incapable of permeating cell membranes, or which display direct toxicities would be also eliminated. However, the work with the cell-line based models is rigged with fundamental shortcoming: human body is built using many hundreds of cell types, while commonly established cell cultures are typically homogenous.
One way to bridge this gap is to perform secondary screens in the cells representing the tissues most commonly contributing to a systemic toxicity which may arise when whole body is exposed to a novel pharmaceutical. The culprit is often the liver, which is responsible for biotransformation of a majority of xenobiotics. Direct toxicity to the hepatic parenchyma is also quite common. Historically, approximately 20–30% of all drug withdrawals from the US and EU markets are due to hepatotoxicity, with drug-induced liver injury (DILI) contributing at least 40% to the number of the withdrawals in the United States (Olson et al., 2000; Peters, 2005). Ideally, potential drug toxicities should be discovered during preclinical testing in cellular or animal models. Nevertheless, many drugs were found to cause injury to human liver only after marketing, and subsequently either discontinued or received the warning label. Whether the failure of preclinical modeling is due to human genetic variants, immune reactions or disease-related metabolic problems, the animal models are limited in detecting human-specific phenomena. In addition, there is also a strong push to minimize the use of animal models due to ethical concerns (Langley et al., 2015).

Therefore, in this review we concentrate on liver cell-based platforms amenable to standardizing for their eventual use in toxicity screening compatible with HTS mode. This goal can be achieved with the development of “liver-on-a-chip” devices with embed human cells. Such platform may be useful both at the earliest steps of drug development (Fig.1), which embraces the paradigm of “failing early-failing cheaply”, and at further development stages, where it will eventually reduce the use of animals.

![Fig. 1: HTS-based drug discovery paradigm](image)

2 Human liver metabolism differs from that of animals

Liver is an intricate factory built by a variety of cooperating cells which perform over 500 distinct functions, including large scale synthesis of various blood components, the metabolism of glucose, fatty acids and cholesterol, the production of bile, and the detoxification/biotransformation of endogenous and exogenous substances. Of all the important liver functions, its metabolism — especially that of pharmaceutical drugs and other xenobiotics — is perhaps the most important in the context of pharmaceutical toxicology. In hepatic parenchyma, xenobiotics undergo three phases of metabolism and transport: (1) Phase I, which is mainly catalyzed by the cytochrome P450 enzymes (CYP450) and results in transformation of lipophilic compounds into water-soluble metabolites; (2) Phase II, where various enzymes conjugate xenobiotics and/or their metabolites to highly polar molecules such as glucose, glucuronic acid, sulfate, or glutathione; (3) Phase III, where specific or non-specific transporters efflux these highly polar metabolites out of hepatocytes into the bile, or release them to the blood for subsequent excretion with urine. Extreme diversity of Phase II enzymatic system is a root cause for poor predictive performance of cell-based hepatotoxicity assays for possible adverse effects of potential drugs in humans.
Although Phase I reactions may be carried out by any combination of 50 cytochrome P450 (CYP450) monooxygenases, some of these enzymes are more important than others. Six cytochromes, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5, are capable of metabolizing 90% of known drugs (Liddle and Stedman, 2007; Lynch and Price, 2007). Both isoenzyme profile of these cytochromes and relative catalytic activity within a particular source of the liver material are most critical for the standardization and for proper functioning of the “liver-on-a-chip” device.

Phases I and II are commonly referred to as “metabolic detoxification,” which is a misnomer, as many xenobiotics are metabolized into either bioactive or toxic compounds. Recapitulation of the liver drug metabolism in vitro is the pivotal aim for a “liver on a chip” development. Ideally, preclinical assays would require use of highly standardized cellular component; at the end, the potencies and other characteristics of various drugs should be compared one to another across the batches of disposable devices. The easiest way to standardize biological component of the chip without reverting to cell immortalization is to use the cells prepared from inbred animals, for example, a particular strain of mice. Unfortunately, the comparison of the content of nine CYP450 enzymes in the microsomes derived from hepatic specimens procured from mouse, rat, rabbit, dog, micropig, and monkey revealed that no single model species resembles enzyme activities in human liver (Bogaards et al., 2000). Moreover, the metabolic abilities of Phase II enzymes also markedly differ among species as it was demonstrated for UDP-glucuronosyltransferase (UGT) activity (Hanioka et al., 2016), as well as for sulfation and glutathione conjugation (Miller et al., 1993).

Therefore, we would have to create “liver chips” with the aid of the cells of human origin. Let us consider how close different preparations of liver cells may resemble human liver (Tab. 1).

Tab. 1: Comparison of cell sources for “liver-on-a-chip” technology

<table>
<thead>
<tr>
<th>Cell source (relevant references)</th>
<th>Primary Hepatocytes (Bell et al., 2017; Hart et al., 2010)</th>
<th>UpCyte® (Ramachandran et al., 2015b; Herzog et al., 2016; Schaefer et al., 2016, 2018)</th>
<th>HepG2 (Gerets et al., 2012; Hart et al., 2010)</th>
<th>Differentiated HepaRG (Bell et al., 2017; Gerets et al., 2012; Hart et al., 2010; Le Vee M. et al., 2006)</th>
<th>iPSC derived (Baxter et al., 2015; Chaudhari et al., 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic similarity to human hepatocytes</td>
<td>Exact (derived from particular individual)</td>
<td>Exact (derived from particular individual)</td>
<td>Medium (derived from hepatoblastoma with abnormal karyotype and highly malignant phenotype)</td>
<td>High (quiescent, differentiated cancer cell line with stable sub-diploid karyotype with minimal alterations)</td>
<td>Exact (derived from particular individual)</td>
</tr>
<tr>
<td>Variability</td>
<td>High</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Standardization</td>
<td>Impossible</td>
<td>Possible</td>
<td>Impossible</td>
<td>Possible</td>
<td>Impossible</td>
</tr>
<tr>
<td>Use in personalized medicine</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Supply</td>
<td>Limited</td>
<td>Unlimited</td>
<td>Unlimited</td>
<td>Relatively unlimited</td>
<td>Unlimited</td>
</tr>
<tr>
<td>Viability</td>
<td>10-14 days</td>
<td>10 -14 days</td>
<td>7 days</td>
<td>30 days</td>
<td>2-4 days</td>
</tr>
<tr>
<td>Number of passages</td>
<td>n/a</td>
<td>40</td>
<td>Unlimited</td>
<td>20 to preclude instability</td>
<td>50</td>
</tr>
<tr>
<td>Functional stability</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Unknown</td>
</tr>
<tr>
<td>P450 enzymatic profile</td>
<td>1A2, 2A6, 2C8, 2B6, 2C19, 2C8, 2D6, 2E1, 2C9, 3A4, 3A5, 3A7</td>
<td>1A2, 2C8, 2B6, 2C19, 2C9, 2D6, 3A4</td>
<td>1A2, 2C8, 2B6, 2C9, 3A5, 3A7</td>
<td>1A2, 2A6, 2B6, 2C19, 2C8, 2E1, 2D6, 2C9, 3A4, 3A5, 3A7</td>
<td>1A2, 2A6, 2B6, 2C19, 2C8, 2E1, 2D6, 2C9, 3A4, 3A5, 3A7</td>
</tr>
<tr>
<td>Total P450 activity</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Medium</td>
<td>Relatively low, as in fetal hepatocytes</td>
</tr>
<tr>
<td>Transporters</td>
<td>ABCBA, ABCB7, ABCB3, ABCB1, ABCC1, ABCC2, ABCC3, ABCE1, ABCF1, ABCF2, GTR1, SLCO1B1, SLC22A1</td>
<td>ABCF3, ABCB1, ABCC1, ABCC2, ABCE1, ABCF1, ABCF2, GTR1, SLCO1B1, SLC22A1, SLC47A1</td>
<td>ABCF3, ABCB1, ABCC1, ABCE1, ABCF1, ABCF2, GTR1</td>
<td>ABCBA, ABCB7, ABCB3, ABCB1, ABCC1, ABCC2, ABCC3, ABCE1, ABCF1, ABCF2, GTR1, SLCO2B1, SLCO1B1, SLC10A1</td>
<td>ABCBA, ABCB7, ABCB3, ABCB1, ABCC1, ABCC2, ABCE1, ABCF1, ABCF2, GTR1, SLC10A1</td>
</tr>
<tr>
<td>Generation of reporter lines</td>
<td>Impossible</td>
<td>Possible</td>
<td>Possible</td>
<td>Possible with limitations</td>
<td>Possible</td>
</tr>
</tbody>
</table>
3 Liver cells and cell lines: available choices

Liver slices and whole perfused organs preserve an intact tissue structure, thereby being the most physiologically realistic model. However, their standardization and long-term maintenance have proven close to impossible. However, some reliable approximation of the liver could be achieved with the aid of microfabrication and advanced tissue engineering, capable of the generation of “on-a-chip” tissue and organ models suitable for HTS purposes. Of note, these models can be imaging and analysis-friendly as they allow for real-time monitoring of the state of the living cells and their extracellular environment. A successful platform for mimicking liver physiology and hepatic drug metabolism in vitro is expected to replicate all major liver functions by controlling cellular dynamics over a prolonged period of time, which is currently defined as more than 28 days.

3.1 Hepatocytes

Human hepatocytes represent nearly 60% of the total cell population within the liver. These cells, capable of performing a majority of liver functions, could be isolated from the human liver via collagenase perfusion. Primary hepatocytes are commonly accepted as the “gold standard” for constructing liver models for drug testing and other applications. Maintaining an in vivo-like phenotype for isolated hepatocytes is challenging, since in a monolayer culture, these cells undergo significant changes in phase I and II metabolism and lose function over 72 hours (Rodríguez-Antona, Donato et al., 2002). Moreover, cultured primary hepatocytes may also lose their polarization, which would, in turn, greatly affect their ability to efflux biotransformed compounds (Luttringer et al., 2002; Noel et al., 2013). Luckily, both widely used well-differentiated human hepatoma cell line HepaRG cell line and primary human hepatocytes retain their polarization even in monolayers, as it is evident by differential expression of a proper set of influx and efflux transporters at its sinusoidal and canalicular poles, respectively (Le Vee et al., 2013, 2015).

Functional life of hepatocyte may be prolonged by a variety of techniques. One promising approach is to culture them as spheroids, through inhibiting hepatocyte attachment to vessel walls and, thereby, enforcing their floating as aggregates. Spheroids may be formed by mechanical agitation by rotary shaker or spinner flask, hanging drop or using non-adherent surface chemistry. Hepatocellular spheroids retain a majority of the parenchymal functions, including the secretion of albumin, urea, transferrin, and bile, along with Phase I and II biotransformation activity, for at least three weeks after seeding (Arakawa et al., 2017), which make them suitable for the cytochrome induction tests. Hepatocyte spheroids are compatible with a serum-free medium and co-culturing with non-parenchymal Kupffer, stellate and biliary cells (Bell et al., 2016). Heterotypic spheroids reflect tissue environments in vivo, and, at least theoretically, permit construction of larger tissue models by higher order assembly of individual spheroids. In composite spheroids, optimal ratio of the hepatocytes and the type I collagen microparticles is approximately one to one; the shift towards more of the collagen microparticles compromises hepatocyte functions (Yamada et al., 2015). On the other hand, an optimal co-culturing ratio for hepatocytes supported with endothelial progenitor cells is at 5:1, in presence of alginate-collagen (Chan et al., 2016). Another recent work used a 3D printing technique to combine alginate hydrogels with primary hepatocytes and mesenchymal stem cells (MSCs). This approach improved the viability of isolated hepatocytes to more than 90% and their morphological stability to up to 7 days (Kim et al., 2018).

Another hepatic modeling approach is based on the sandwich cultures, also known as overlays. Sandwiching hepatocytes between two layers of ECM leads to formation of the “plate” structures similar to the liver anatomy in vivo. Planar structure of the sandwich provides for an ease of microscopic imaging. This technique preserves the polarity, including basal surfaces induced by ECM layers and apical surfaces by cell-to-cell contact, leads to the development of the canalicular network and the secretion of bile (Swift et al., 2010). In sandwich cultures, the viable period may be increased to up to 6–8 weeks. However, sandwiched hepatocytes maintain their biotransformation activities and the ability to induce many Phase I and Phase II enzymes for the first two 2 weeks only. Culturing primary hepatocytes within 3D structures formed by porous poly(L-lactide-co-glycolide) (PLGA) nanofibers chemically modified type I collagen that mimics the natural liver environment is a promising strategy to improve the synthetic function of the liver cells over time (Brown et al., 2018).

In a recent study, primary human hepatocytes grown in a sandwich overlaid with extracellular matrix, were directly compared to that in 3D spheroids in repeated-dose toxicity studies using 5 different liver toxins. To ensure robustness of the findings, the study has been performed in six different using cryopreserved cells collected from the same set of donors. The study showed superiority of spheroids in expression of ADME-related proteins, as well as in catalytic activities of five different cytochromes (Bell et al., 2018).

3.2 Upcyte® hepatocytes

The Upcyte® (“upregulated”) technology involves virus-guided introduction of a unique combination of genes that induce and maintain cell proliferation until the cells reach confluence. This allows the primary cells to be passaged many times with the generation of billions of cells. Human Upcyte® hepatocytes1 are primary human hepatocytes derived by transducing expressing E6 and E7 proteins of human papillomaviruses, which release hepatocytes from cell-cycle arrest and allow their proliferation in response to Oncostatin M (OSM), a member of the interleukin 6 (IL-6) superfamily involved in liver regeneration. In cultures, Upcyte® hepatocytes undergo a finite number of cell divisions without being immortalized or losing adult primary cell phenotype (Burkard et al., 2012). Upon stimulation with OSM, doubling time for these cells is between 33 and 49 hours. After OSM is withdrawn, Upcytes differentiate to generate highly functional cells. This method allows expanding human hepatocytes

1www.upcyte.technologies.com
for 35 population doublings, resulting in $10^{15}$ (a quadrillion) cells from each liver biopsy. Over 12 billion Upcyte® hepatocytes can be generated from one vial of primary human hepatocytes, thus meeting the high demand for standardized cells necessary for HTS studies. In the first-generation upcyte® hepatocytes, cytochromes CYP1A2, CYP2B6, and CYP3A4, but not CYP2B6, were drug-inducible at the mRNA level, suggesting the necessity for additional optimization. Second-generation Upcyte® hepatocytes (Levy et al., 2015) form metabolically functional, polarized cultures with functional bile canaliculi and expression profiles for nuclear receptors, Phase 1 and 2 enzymes, and drug transporter genes comparable to that in primary human hepatocytes. As with the first-generation Upcyte® hepatocytes, second-generation cells lack fetal markers and express cytokeratin 8 and 18, human serum albumin and store glycogen (Levy et al., 2015).

Upcyte technology opens new horizons in modeling organotypic cultures. In a recent report, functional 3D hepatic structures were generated using a defined mixture of three types of differentiated human Upcyte® cells, namely hepatocytes, liver sinusoidal endothelial cells (LSECs) and mesenchymal stem cells (MSCs). When all three types of cells were plated on a thick layer of Matrigel™, they self-organized to form liver organoid-like structures within 24 hours; during a 10 day culturing in a bioreactor, these liver organoids showed typical functional characteristics of liver parenchyma including activity of cytochromes P450, CYP3A4, CYP2B6 and CYP2C9 as well as mRNA expression of several marker genes and other enzymes (Ramachandran et al., 2015a).

It is also important to note that Upcyte® hepatocytes can be transformed with reporter constructs to permit real time monitoring of hepatocyte functions and/or drug effects.

### 3.3 HepG2 cells

The HepG2 cell line was derived from a hepatocellular carcinoma of a 15-year-old Caucasian male. Due to low endogenous expression of cytochromes, HepG2 cells are a relatively poor choice for detection of hepatotoxicity (Wilkening et al., 2003) (Tab. 1). Even when HepG2 cells are made to express cytochromes forcibly, via adenoviral transfection, these cells do not reach liver model standards, as they also lack activity of aldolase B; several drug transporters such as BSEP, OATP-C, NTCP, and OCT-1; and a range of non-cytochrome Phase II enzymes, such as GSTA 1/2 and GSTM1 (Gripon et al., 2002; Guillouzo et al., 2007; Wilkening et al., 2003).

Historically, HepG2 cells were extensively exploited to examine cytoprotective, antioxidative, hepatoprotective, anti-hepatoma, hypocholesterolemic, anti-steatosis, bioenergetic homeostatic and anti-insulin resistant properties of various bioactive compounds of chemical and botanical origin (Kaur et al., 2018). Due to high content of organelles and mtDNA, HepG2 cells remain a model of choice for investigation of mitochondrial toxicity through evaluations of mitochondrial fragmentation, lysosome content and mitophagy as well as mitochondrial release of cytochrome c, leading to apoptosis and/or necrosis (Paech F et al., 2018; Paemanee A. et al., 2017). Because of that, attempts to improve the overall performance of HepG2 are continued, with the chief strategy to overcome their limitations being the development of three dimensional (3D) models, including co-culturing (He et al., 2018) and generation of the spheroids maintained in the hanging drops or otherwise (Hurrell et al., 2018; Shah et al, 2018).

### 3.4 HepaRG cells

Although the HepaRG cell line was derived from a hepatoma of a female patient with cirrhosis following hepatitis C virus infection (Gripon et al., 2002), unlike other human liver cell lines, HepaRG cells express many drug processing genes at levels similar to those in primary human hepatocytes. In particular, HepaRG express various nuclear receptors, transporters, and specific markers of adult hepatocytes (albumin, haptoglobins, and aldolase B) (Guillouzo et al., 2007). In confluent cultures, HepaRG cells differentiate from a stem cell/progenitor state to mature hepatocytes and primitive biliary cells and maintain a relatively stable function for several weeks (Jossé et al., 2008). HepaRG cells, including 3D-organotypic HepaRG cultures obtained using a scaffold-free, high-throughput hanging drop system are considered a viable option for evaluating hepatotoxic chemicals with reproducible responses (Guinness et al., 2013).

A high-throughput transcriptional profiling of both differentiated and undifferentiated HepaRG cells found that these cells have much higher resemblance to primary human hepatocytes and biopsied livers that HepG2 (Hart et al., 2010). These transcriptomics data has been recently supported by the proteomics: a global proteomic analysis of HepG2, upcyte, and HepaRG showed that both HepG2 and upcyte had their cytochrome activity levels reduced by 90% of that in primary hepatocytes, while HepaRG cells had these levels reduced by 60% (Sison-Young et al., 2015). Remarkably, HepaRG cells also retained expression of MRP3 and P-gp (MDR1) transporters.

Molecular profiling data described above indicate that the HepaRG cell line in many ways resembles human primary hepatocytes, which is encouraging for utilization of these cells in the studies of xenobiotic metabolism, hepatotoxicology, and hepatocyte differentiation. It is, however, important to note that HepaRG cells eliminate galactose/sorbitol and produce albumin at rates higher than in primary hepatocytes, while being unable to excrete urea (Lüllberstedt et al., 2011). As HepaRG cells are a clone derived from a particular individual, it is not surprising that the levels of cytochrome activities and their relative inducibility in these cells match some primary hepatocyte cultures but not others (Berger et al., 2016; Hart et al., 2010; Lüllberstedt et al., 2011; Sison-Young et al., 2015). These differences are most likely intrinsic as they reflect variation in the expression levels of individual cytochromes across healthy humans.
3.5 Induced pluripotent stem cells (iPSC)

Induced pluripotent stem cell (iPSC) technology was introduced in 2006 (Takahashi and Yamanaka, 2006). iPSCs originate from adult cells reprogrammed by introduction of several genes essential for embryonic stemness, namely Oct3/4, Sox2, c-Myc, and Klf4. Similar to embryonic stem cells, iPSCs can be differentiated into endoderm, mesoderm, or ectoderm. This technology has important implications for drug toxicology (Anson et al., 2011). In particular, utilization of iPSCs in drug testing addresses the main problems arising from utilization of primary cells, such as limited quantities, donor o donor variation and relatively short lifespan in vitro, and circumvents ethical requirements since these cells do not come from embryo (Shafriz et al., 2009). iPSCs allow to build surrogate liver panels to represent most common combinations of Phase II enzyme variants and, therefore, to evaluate the potential of adverse drug reactions in the population and to provide an additional step toward personalization of medicine. Thus, iPSCs may help to identify the potential for idiosyncratic hepatotoxicity which may develop in some patients but not others – something which may be missed in course of typical hepatotoxicity studies.

Since 2009, when the first protocol for the production of iPSC derived hepatocyte-like cells was published (Song et al., 2009), a variety of optimizing modifications to the standard procedure were proposed (Chen et al., 2012; Chin et al., 2009; Huang et al., 2014; Liu et al., 2010; Schwartz et al., 2014; Si-Tayeb et al., 2010; Takayama et al., 2012). Remarkably, some of these modifications simplified the workflow: instead of differentiating the cells in the presence of serum, supplemented with growth factors and small metabolites, the protocols shifted towards greater standardization, with elimination of primary feeder cell requirements and introducing serum-free media.

iPSC-derived hepatocyte-like cells maintain a majority of hepatocytic function, including the production of albumin, expression of cytochromes, and the storage of glycogen, while displaying global expression profiles resembling those of primary human hepatocytes (Gao and Liu, 2017). However, transcriptomic analyses revealed that for certain functional gene sets, the expression patterns of iPSC and of cultured primary hepatocytes differ substantially, with genes related to endocytosis upregulated (Bell et al., 2017), and cytochrome production downregulated (Bell et al., 2017; Si-Tayeb et al., 2010). Another aspect that limits wide utilization of iPSCs in drug testing is the standardization issue. Genetics of each iPSC line reflects the epigenetic profiles, miRNA patterns and differentiation properties (Chin et al., 2009; Marchetto et al., 2009; Miura et al., 2009), which greatly contribute to lab-to-lab variations typically observed in toxicological studies. Furthermore, the efficiency of iPSC differentiation into hepatocytes is at 60% even when best protocols are used (Chistiakov and Chistiakov, 2012) deriving the line requires expensive and time consuming extraction and purification steps.

To overcome mentioned limitations, Cellular Dynamics International (CDI) has developed 95% pure iPSC derived iCell® Hepatocytes, which are claimed to closely resemble primary cells. However, recent comparative study of these cells along with HepaRG and human hepatocyte co-cultures showed that their metabolic activity is more than tenfold lower and approximates one detected in HepG2 (Kratochwil et al., 2017), which may be assessed via fluorescence imaging techniques that rely on a combination of nuclear and cytosolic dyes; (b) The retention of toxicologically-relevant metabolic profile with stable activity of Phase I and Phase II enzymes; (c) Drug transporter activity, which should be taken into consideration place during initial vetting of an in vitro platform for studies of drug metabolism; (d) Secretory capacity which is approximated by albumin biosynthesis and urea excretion. Notably, a consistently high albumin production at the levels of approximately ~1–5 μg per 10^6 cells per hour serves as indispensable indicator of the overall metabolic health of the cells; urea plays a similar role for evaluating general metabolic capacity. To directly detect albumin secreted by hepatocyte culture, a 3D Scaffold-Based Immunoassay Chips have been developed recently (Yan et al., 2015).

As can be seen from Table 1, the standardization requirements are fulfilled only by Upcyte and HepaRG cells, with HepaRG being even closer in their cytochrome and transporter profiles to primary hepatocytes than the Upcyte cultures. To fully standardize the cell behavior in the “liver-on-a-chip” devices, there is a need to collect the data concerning their exposures to the panel of at least 100 drugs, roughly divided into four categories that include safe and efficacious, safe and non-eficacious, non-safe and efficacious, and non-safe and non-eficacious compounds, all with well characterized metabolism in vivo. Moreover, each drug has to be studied in a range of concentrations, to determine both acute and chronic effects. In other words, both IC50/LD50 and a variety of the biomarkers of functional impairment have to be assessed.

4 Cell line standardization problem

An induction of “liver-on-a-chip” technology into the main aisle of toxicology labs is critically dependent on our ability to standardize the cells seeded on to the chip. In principle, cell standardization requires the stability and reproducibility of the four main characteristics: (a) Viability for prolonged periods of time which may be assessed via fluorescence imaging techniques that rely on a combination of nuclear and cytosolic dyes; (b) The retention of toxicologically-relevant metabolic profile with stable activity of Phase I and Phase II enzymes; (c) Drug transporter activity, which should be taken into consideration place during initial vetting of an in vitro platform for studies of drug metabolism; (d) Secretory capacity which is approximated by albumin biosynthesis and urea excretion. Notably, a consistently high albumin production at the levels of approximately ~1–5 μg per 10^6 cells per hour serves as indispensable indicator of the overall metabolic health of the cells; urea plays a similar role for evaluating general metabolic capacity. To directly detect albumin secreted by hepatocyte culture, a 3D Scaffold-Based Immunoassay Chips have been developed recently (Yan et al., 2015).

As can be seen from Table 1, the standardization requirements are fulfilled only by Upcyte and HepaRG cells, with HepaRG being even closer in their cytochrome and transporter profiles to primary hepatocytes than the Upcyte cultures. To fully standardize the cell behavior in the “liver-on-a-chip” devices, there is a need to collect the data concerning their exposures to the panel of at least 100 drugs, roughly divided into four categories that include safe and efficacious, safe and non-eficacious, non-safe and efficacious, and non-safe and non-eficacious compounds, all with well characterized metabolism in vivo. Moreover, each drug has to be studied in a range of concentrations, to determine both acute and chronic effects. In other words, both IC50/LD50 and a variety of the biomarkers of functional impairment have to be assessed.
5 Limitations imposed by culturing

Until recently, liver cell monocultures were a mainstay of toxicology practice for a number of well-defined “fit-for-purpose” assays. Nowadays, however, it is widely recognized that single cell type monolayers do not reflect a complexity of the tissue developed within the living organism. The limitations of hepatocyte monocyteculture are obvious. One of the most promising approaches to overcome the issues with viability of hepatocytes monocyteculture is the utilization of microfluidic perfusion devices (Knöspel et al., 2016; Shulman and Nahmias, 2013; Tehranirokh et al., 2013; Wagner et al., 2013). Unfortunately, for a majority of cell types, common cultivation period still does not exceed 14 days. Recently Klein et al. have demonstrated that HepaRG cells can be maintained in optimized serum-free media for 30 days without the decline in their viability (Klein et al., 2014). This finding certainly opens up the opportunity for the use of these cells in systems toxicology.

Both viability and functioning of hepatocytes are reduced in the absence of non-parenchymal cells. These supportive cells include fibroblasts, endotheliocytes, stellate and Kupffer cells, and biliary epithelial cells (Ries et al., 2000; Soto-Gutierrez et al., 2010). Importantly, an addition of even one type of auxiliary cell often helps. For example, Okamoto et al. developed a coculture system of primary human hepatocytes with hepatic stellate cell line L90 (Okamoto et al., 1998), which has retained a substantial activity of P450 cytochromes for at least 2 weeks, however, no rescue of urea excretion was noted. In another study, primary human hepatocytes were co-cultured with human umbilical vein endothelial cells (HUVEC) to achieve marked improvement of albumin production, urea biosynthesis and the rate of diazepam biotransformation (Salerno et al., 2011). Kostadinova et al. developed a 3D mixed culture of primary hepatocytes with a variety of non-parenchymal cell types (Kostadinova et al., 2013). This liver-like culture maintained the production of albumin, fibrinogen, transferrin and urea for up to 3 months, while retaining ability to induce the synthesis of cytochrome P450 on a drug exposure cue.

From a standpoint of liver biology, non-homotypic cultures have better chance to correctly predict drug-induced liver injury as its development often depends on the communication between hepatocytes and the resident macrophages, which, on exposure to certain drug metabolites may be activated to serve as intracellular sources of inflammation (Endo et al., 2012; Kegel et al., 2015). Indeed, previously mentioned 3D liver equivalents containing a variety of non-parenchymal cells, including Kupffer macrophages, already demonstrated their value in detection of potential inducer of idiosyncratic liver injury (Kostadinova et al., 2013). Similar results were obtained for micropatterned co-cultures containing either primary human hepatocytes or iPSC-derived hepatocytes and murine fibroblasts (Ware et al., 2015).

It is important to note that the hepatocyte-produced drug metabolites may not be toxic for liver cells, while exerting adverse effects on other organs and tissues. To address this problem, several heterotypic cell cultures have been developed. For example, a microfluidic-based platform for co-culture of neurospheres and liver equivalents was recently employed in a two-week assay with a repeated exposure to the neurotoxic 2,5-hexanodione to show a significantly higher sensitivity compared to either hepatocyte or neurosphere monocultures (Materne et al., 2015). The same group also developed a platform for co-culture of liver organoids with skin (Wagner et al., 2013). On a microfluidic chip for the co-culture of HepaRG and kidney cells (MDCK) created by another group (Choucha-Snouber et al., 2013), a 3-day exposure to ifosfamide led to the detection of apparent nephrotoxic effects, while no toxicity was observed in monocultured MDCKs. In spheroid co-culture of HepaRG with primary human hepatic stellate cells (HSCs), an exposure to the pro-fibrotic compounds allowed the detection of multiple fibrotic features such as HSC activation, collagen secretion and deposition, thereby providing an avenue for in vitro testing of the possible contributors to liver fibrosis (Leite et al., 2016).

6 The way to improve hardware

The need for better detection and instrumentation, as well as better materials, stems from the need to pump controlled microliter volumes of the media through the chip circuits, and in particular, to distribute the flow at critical junctions with high degree of precision. Most scientists agree that devices of 100 μm in height or less are preferable since at that scale they approach the diameter of the liver sinusoids, which is in the order of 5–10 μm. At this height, the problems with the signal and/or metabolite dilution which plague larger-scale platforms are reduced.

An interpretation of the data generated with the aid of a microfluidic device critically depends on correct scaling of physical and physiological parameters and on relevance of selected computational model of drug response and toxicity. One of the most important parameters which control the adsorption, distribution, metabolism, excretion and toxicity (ADMET) in physiological systems is the exposure time of the tissue to drugs and other xenobiotics which is called the organ-specific transit time. According to initial model generated in 1963 after experimentation on dogs, liver-specific transit time is between 10 and 20 seconds (Goresky, 1963). However, later studies demonstrated that in humans the hepatic transit time is substantially longer, from minutes to hours (Chiu, 1983). Moreover, hepatic transit time depends on a structure of a compound (Chiu, 1983) and may vary between individuals, being influenced by their genetics and overall state of health (Pedersen et al., 2005). Accordingly, to mimic in vivo ADMET characteristics in the fluidic systems, one has to have an ability to change fluidic residence times to match them with the required physiological values.

To evaluate drug metabolite-induced toxicity, more complicated fluidic systems are necessary (Fig. 2) (Marx et al., 2016). Multi-parametric evaluation of the drug effects may include the studies of intestinal permeability, biotransformation pathway as well as the tests for the toxicity of a drug and its metabolites (Semenova et al., 2016; Zakhariants et al., 2016). Employing a combination of different cell types which reflect tissue-tissue interactions observed in whole organisms could significantly add to
the value of the collected data. However, the disadvantages of multi-cell type devices stem from their underlying complexity and include low throughput and questionable scalability.

Detection in the microfluidic platforms is a challenge. In order to capture both acute and chronic effects of exposure to drugs, toxins or environmental factors, successful “liver-on-a-chip” device should sum and present the data stream collected in real-time. On top of that, due to cell to cell differences observed in all types of culture, quantitative monitoring of intracellular changes and cell-cell interactions should be performed per cell basis, rather than in bulk. Growing trends of single-cell transcriptomics and the biochip compatible reporters, are, in part, catering to this need.

One of the approaches to explore intracellular changes might be microRNA level monitoring in the culture medium of the microfluidic platform. MicroRNA (miRNA) is a class of small non-coding RNAs which mediate post-transcriptional gene silencing by sequence-specific inhibition of the target mRNAs translation and/or lowering their half-lives in the cytoplasm (Turchinovich et al., 2015, 2016). Together with their binding partners, Argonaute proteins, miRNAs form cores of RNA-induced silencing complexes. Finally, the discovery of cell-free miRNAs in all biological fluids suggests that miRNAs might well act as signaling molecules outside the cell, and may be utilized as biomarkers (Makarova et al., 2014, 2016).

To monitor the state of the hepatocyte cell culture, both hepatocyte-specific microRNAs (miR-122), and miRNA species highly expressed in the liver (miR-21, miR-19a/b, miR-106a/b) may be employed. The change in the representation of these microRNAs in the culture medium may be utilized for sensing a physiological change in the hepatocytes under the influence of the studied compound. Also, a number of microRNAs affecting the expression of ADMET genes were discovered. So, for example, miR-27b and miR-378 (Mohri et al., 2010) regulate the expression of cytochromes 1B1, 2E1 and 3A4. The appearance of such microRNAs in the microfluidic system cell culture media may significantly affect functional capacity of the device.

Metabolomics presents yet another, very interesting alternative for extracting quantitative information about the dynamic metabolic response of the modelled liver to pathophysiological conditions. In two recent studies, the metabolite profiles of HepG2 cells treated with various test substances were analyzed to reveal concentration-response effects mapped to a variety of the response patterns consistent with different liver toxicity mechanisms (García-Cañaveras et al., 2016; Ramirez et al., 2018).

On the other hand, spatiotemporal dynamics of multicellular milieu could be monitored with an aid of a small fluorescent molecule (probe) or a protein-based fluorescent biosensor. In this respect, reporter cells have a great promise; such cells natively fluoresce upon stimulation, or under certain stress conditions, thus revealing specific information about the state of the cell. Optical interrogation of the hepatocyte culture with integrated “sensor” cells engineered to respond to particular signals may provide a way to extract this type of information in a real-time format.

![Microfluidic platform](image)

Fig. 2: Microfluidic platform for long-term multi-tissue coculture with closed circuit

7 **Biochip compatible reporter assays.**

One of the most important trends in drug discovery is a switch from the “one disease – one target” mentality to the understanding that the diseases are driven by shifts in a homeostatic balance. Even the smallest of these changes may involve many interacting genes and proteins upstream and downstream of a malfunctioning element in a biological puzzle. Hence, focus of the HTS efforts also shifted toward a search for various modulators which exert their action either through fine-tuning various transcription factors, or by controlling epigenetics landscapes. Cell-based reporter-enabled biochips are ideally suited for the purpose of HTS for activators and inhibitors of transcription factors. Reporters with fluorescent labels are preferable for the use on the “liver-on-a-chip” devices, since they permit monitoring of the reporter response in intact cells. However, recent
development of the cell-permeable reagent for Renilla luciferase (Lindberg et al., 2013) opens the possibility of measuring luminescence within the intact cells.

The choice of reporter constructs for transforming hepatocyte-like cell lines is wide (Tab. 1). In particular, classic promoter-based reporters comprised of a fluorescent or luminescent protein gene under the promoter of a gene of interest, are readily available from commercial sources. Such promoter-based reporters are useful for monitoring of expression, and had been recently employed to monitor activation of CYP genes in HepG2 and HepaRG cells (Tsuij et al., 2014). Chief disadvantage of these reporters is relatively low level of signal, which is often detected with a substantially delay due to the time necessary for promoter activation, then the transcription and translation of the reporter protein. Another problem is that many genes require for proper expression either relatively large promoter regions, or even the presence of distant enhancers, which cannot be spliced into the plasmid- or virus-based reporter construct due to size limitation. This limitation could be surmounted by using bacterial artificial chromosome (BAC) transgene-based cell lines with very large, locus-wide holding capacity inclusive to all regulatory elements ensuring the normal physiological regulation of a fluorescent or luciferase reporter expression (Poser et al., 2008). The Bssl2-GFP and Srxn1-GFP BAC reporter assays were successfully employed to differentiate between two different types of the response to genotoxic agents in many stably transfected cell lines (Hendriks et al., 2012). Recently, feasibility of BAC-reporter approach has been evaluated by testing of over 2000 FDA approved drugs and active natural product compounds on the modulation of the Srxn1-GFP reporter in HepG2 cells (Wink et al., 2014). Integration of BAC-reporters into the cell component of the “liver-on-a-chip” devices is expected in the nearest future. The most current panel of BAC-GFP modified HepG2 cells, each complete with an upstream sensor, downstream transcription factor and their respective target gene, include reporters for the oxidative stress response pathway (Keap1/Nrf2/Srxn1), the unfolded protein response in the endoplasmic reticulum (Xbp1/Atf6/Bip/Cip) and the DNA damage response (53bp1/p53/p21) (Wink et al., 2017).

Another way to overcome the size-limitation obstacle is to use a fusion-based reporter, which, typically, is comprised of either fluorescent or luminescent protein label enjoined with a full-size protein of interest expressed under a constitutive promoter, for example, p-3. These reporters permit monitoring the half-life and the trafficking of the protein in the living cell. The overwhelming problem with these types of reporters is that the fused protein is fully physiologically active, and often is capable of disturbing the intracellular balance, thus, triggering an expression of the downstream genes and significantly shifting the transcriptomic and proteomic profile of the cells. In turn, these shifts reflect upon the efficacy and toxicity profiles obtained for the drugs under study. Another drawback of the fusion systems is that the promoter is constitutively active, often leading to overexpression of the construct way over the physiological limits and resultant perturbation of cell homeostasis.

Yet another type of reporters has been developed for the monitoring of transcription factors regulated by ubiquitination and proteasomal degradation. The concept for these reporters is shown in Fig. 2. In a nutshell, it is a fusion, where a luminescent or fluorescent label is added to isolated ubiquitination machinery recognition domain instead of complete target protein. As recognition domain has no affinity for DNA, it does not activate the specific program regulated by a particular transcription factor, even when overexpressed. There is still a possibility that overexpression of the recognition domain may serve as a decoy for ubiquitination machinery, hence, to at least some degree stabilizing the endogenously expressed transcription factor, but these effects are usually negligible.

Among transcription factors regulated by ubiquitination and proteasomal degradation, there are three which are directly relevant to monitoring performance of hepatocytes embed into “liver-on-a-chip” devices. These are the transcription factors Nrf2, HIF (hypoxia inducible factor), and NF-kb.

7.1 Nrf2

Nrf2 (nuclear factor erythroid 2–related factor 2) orchestrates the antioxidant response by inducing the expression of cytoprotective, pro-survival proteins such as thioredoxin reductase, glutathione reductase, glutathione S-transferase (GST), hemeoxygenase-1 (HO1), catalase and others. Under homeostatic conditions, Nrf2 is sequestered by binding to its inhibitory protein, Keap1 (Kelch-like ECH-associated protein-1). Keap1 serves as a bridge between Nrf2 and the Cul3-Rbx1 E3 ubiquitin ligase, which permits polyubiquitination of the lysines positioned within the central α-helix of the Neh2 recognition domain. As a result of oxidative/electrophoretic stress, active cysteines of Keap1 are modified, and Nrf2 protein is released for subsequent translocation to the nucleus, where it induces the expression from the promoters with the antioxidant response elements (ARE) (Kaspar et al., 2009).

Importantly, in many primary tumors Nrf2 is constitutively active (de la Vega et al., 2016). Hence, it is not surprising that tumor-derived HepG2 and HepaRG cells overexpress Nrf2-regulated genes. Upcyte cultures do that too, however, to a lesser degree (Sison-Young et al., 2015). When HepaRG were compared to Upcyte cells, Peroxiredoxins 1, 2, thioredoxin reductase and thioredoxin were found to be overexpressed substantially (Sison-Young et al., 2015), indicating that HepaRG cells are protected against effects of the drugs causing glutathione depletion. In other words, drug toxicity estimates obtained while working with HepaRG or HepG2 tend to be a bit more optimistic than they should be.

A reporter for monitoring Nrf2 activation, Neh2-luc (Smirnova et al., 2011; Fig. 3), permits the real time monitoring right after addition, with no lag-period, while being 10-fold more sensitive than ARE-luc reporters (Smirnova et al., 2011). This reporter already found its use in the discovery labs, especially when an estimate of an intracellular alkylating power of a drug is needed. Neh2-luc enabled screening of drug libraries showed that at least 10% of all compounds behave as non-specific Nrf2 activators, meaning that they may alkylate active protein and peptide thiols in general, and glutathione in particular. In other words, administration of these drugs actively shifts the cellular redox balance and triggers the adaptive response. It is expected that Neh2-derived reporter would be fitted with a fluorescent label compatible with “liver-on-a-chip” devices.
7.2 HIF
HIF, a transcription factor capable of activating a battery of genes involved in glucose uptake and metabolism, extracellular pH control, angiogenesis, erythropoiesis, mitogenesis, and apoptosis, is expressed ubiquitously. It consists of 2 subunits, known as HIF1-α and HIF1-β. The levels of HIF1-α are regulated by hydroxylation of its Pro564 and/or 402 residues. This modification serves as a prerequisite for the interaction with the tumor suppressor von Hippel-Lindau (VHL) protein yielding a complex that provides for a rapid HIF ubiquitination and degradation (see review (Kaelin, 2005) and ref therein). HIF hydroxylation is executed by the so-called HIF prolyl hydroxylases represented by 3 isozymes. Upregulation of HIF is an indication of the low oxygen supply and the enactment of Warburg effect, a metabolic shift towards the glycolysis.

![Luciferase fusion reporter concept in the case of NRF2](image)

The luc-reporter with ODD (oxygen degradable domain) of HIF has been developed (Safran et al., 2006), its variant with Renilla luciferase has just become commercially available from Promega. In HTS, employment of HIF1 ODD-luc reporter allowed an identification of the hit with excellent neuroprotective properties later confirmed in in hemorrhagic stroke model in vivo (Smirnova et al., 2010; Karuppagounder et al., 2016). Such kind of reporter might also be utilized for evaluation of substrate specificity of HIF prolyl hydroxylase isoforms and structure-activity relationship studies (Osipyants et al., 2017; Poloznikov et al., 2017; Smirnova et al., 2017). This fact clearly demonstrates superior properties of novel generation of cell-based reporters with respect to drug development. In “liver-on-a-chip” devices, in addition to drug discovery purposes, the reporter can be used to quantitate hypoxia and HIF activation. In hypoxia (or with HIF1 activation by other means), expression of cytochromes P450 and phase II enzymes is down-regulated. This metabolic feature principally effects on drug toxicity profiles; this is especially true for the drugs developed for oncological treatment. Under hypoxia, HepaRG cells have been shown to display metabolic changes similar to that observed in poorly differentiated hepatocarcinomas; therefore, these cells may serve as a suitable in vitro model for testing of anticancer agents in hypoxic versus normoxic conditions (Legendre et al., 2009).

7.3 NF-κB
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) controls both the inflammatory cytokine production and the survival of cells. In an inactive state, NF-κB is complexed with the inhibitory protein IκBα. Activation of IκB kinase (IKK) results in phosphorylation of IκBα protein, and its subsequent ubiquitination, which leads to dissociation of IκBα from NF-κB, and eventual degradation of IκBα by the proteasome. The activated NF-κB is then translocated into the nucleus. Inhibiting NF-κB signaling has a potential for the treatment of cancers and inflammatory diseases. Importantly, persisted activation of NF-κB, which is known as chronic inflammation, is known to be a component of idiosyncratic hepatotoxicity (Jiang et al., 2017). Currently, there is no cell-based reporter to monitor NF-κB activation directly. However, a reporter monitoring degradation of its inhibitory partner IκBα can be constructed under the same principle as Neh2- and HIF ODD- derived reporters. The IκBα-derived reporter can be used for drug discovery and for accessing the drug toxicity, similarly to other reporters of this kind, with a special value for studying idiosyncratic hepatotoxicity in assays of controllable activated NF-κB.

8 In silico modelling of the liver function
There is a significant progress in developing the “liver-on-a-chip” and other liver-emulating technologies. However, the field is still somewhat in its infancy in terms of the standards, procedures and methods for translating the data obtained in vitro into
reliable predictions applicable to human body responses. In parallel to various in vitro efforts, the development of predictive computational models of hepatic metabolism is also under way. Although many models perform quite well on the datasets they were developed on, they sometimes suffer from low statistical performance, with imbalanced sensitivity vs specificity ratios.

Speaking generally, the predictive power of any computational models heavily depends on the quality of the respective training data set. When machine learning approaches are used, bigger datasets are preferable to smaller ones. The frameworks of large-scale screening programs, for example, Tox21, already allowed the development of prediction models with the accuracy of as high as 86.9%, sensitivity of 82.5%, and specificity of 92.9% (Capuzzi et al., 2016; Chen et al., 2012). On the other hand, as larger the dataset is as higher the chance of mislabeling either the chemical structures or their toxicity classes. Consequently, manual trimming of large datasets may lead to improvement of models precision. To expand availability of highly confident data, industry-driven collaborative efforts are required. One example of such efforts is eTOX project which is comprised of a database filled with unpublished toxicity reports donated by 13 members of the pharmaceutical industry along with public toxicology data, and its customizable interface eTOXsys (Sanz et al., 2015). The models developed in the course of the eTOX project are available as possible augments for higher-level predictors. In one recent study, the models for BSEP, BCRP, P-glycoprotein and for OATP1B1 and 1B3 were investigated for their potential to improve the DILI-predicting algorithm. Surprisingly, in this particular case, an integration of the transporter-related data had not significantly improved the performance of resultant model (Kotsampasakou et al., 2017).

Here are some interesting attempts to model the liver “as a whole”, with the homeostasis or the “starting state” of the liver being described by a set of differential equation allowing to be modified as a reflection of the respective change observed under certain disease conditions and immunological states. This approach treats hepatotoxicity as a complex outcome of the factors at play, which includes the genotype of the patient, the drugs he or she being exposed to, and any underlying diseases, for example, steatosis. An example of this type of systemic models would be a VirtualLiver, developed by Strand Life Sciences, which couples equations describing the kinetics of biochemical pathways involved in liver homeostasis with these obtained after collection of a set of in vitro measurements quantifying various drug-induced perturbations (Subramanian et al., 2008). Clearly, this type of approach describes the biological system better than any end point analysis of toxicity as it capable to reflect a steady accumulation of changes which eventually culminate in reaching an irreversible outcome. The development of holistic in silico models which simulate the metabolism of the liver is a necessary step towards an adequate and timely assessment of various chemical entities, natural or synthetic.

9 Conclusion

In this review, we described the approaches to develop “liver on a chip” devices for the prediction of the liver toxicity in humans. These devices may include established immortal cell lines, for example, HepG2 – a “workhorse” of liver toxicology, or its less malignant counterpart HepaRG, unmodified or modified primary human cells, and stem cell–derived hepatocyte-like cells, or iPSC. Like many technologies developing on the interface of applied biology and bioengineering, the “liver on a chip” devices were started in an attempt to produce a “one-fits-all” solution, but eventually ended facing a variety of important dilemmas. In particular, choice of biological material greatly influences both the performance of the devices and the precision of the toxicity reports. Unfortunately, unavoidable manipulations with the living component of the chip lead to activation of the Nrf2 and NF-κb –dependent transcriptional programs, which, in turn, reflect upon the cellular response to environmental stressors. Among other impediments to the development of “liver on a chip” technology are the problems with standardization of cells, limitations imposed by culturing and the necessity to develop more complicated fluidic contours. Fortunately, recent breakthroughs in the development of cell-based reporters, including ones with fluorescent label, permits monitoring of the behavior of the cells embed into the “liver on a chip” devices. Finally, a set of computational approaches has been developed to model both particular toxic response pathways and the homeostasis of human liver as a whole; these approaches pave a way to enhance the in silico stage of assessment for a potential toxicity.

References

Bell, C. C., Lauschke, V. M., Vorrink, S. U. et al. (2017). Transcriptional, Functional, and Mechanistic Comparisons of Stem


ALTEX preprint

published May 28, 2018, version 2
doi:10.14573/altex.1803221


Legendre, C., Hori, T., Loyer, P. et al. (2009). Drug-metabolising enzymes are down-regulated by hypoxia in differentiated...


Scientific Reports 23, 9194. doi:10.1038/s41598-017-09321-y


Conflict of interest statement
The authors declare no conflicts of interest.